ATARA BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-12-31 was 155.00K shares, a 42.59% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-30 was 11.05K shares, a 93.01% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-30 was 22.31K shares, a 92.88% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-31 was 159.35K shares, a 48.51% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 15.99K shares, a 93.52% decline from fiscal 2021.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 246.87K shares, a 8.21% decline from fiscal 2020.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 268.94K shares, a 22.66% decline from fiscal 2019.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 347.72K shares, a 66.92% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2022-12-31 | 15.99K shares 10-K · filed 2024-03-28 | |
| 2021-12-31 | 246.87K shares 10-K · filed 2023-02-08 | |
| 2020-12-31 | 268.94K shares 10-K · filed 2023-02-08 | |
| 2019-12-31 | 155.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 347.72K shares 10-K · filed 2022-02-28 |
| 2019-09-30 | 11.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 462.70K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | 22.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 609.86K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | 159.35K shares 10-Q · filed 2019-05-09 | 901.04K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | 269.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 1.05M shares 10-K · filed 2021-03-01 |
| 2018-09-30 | 158.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 841.32K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | 313.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 683.11K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | 309.50K shares 10-Q · filed 2019-05-09 | 369.62K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | 60.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 60.13K shares 10-K · filed 2020-02-27 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 0.00 shares derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | 16.50K shares derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-08 | 17.70K shares derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | 18.95K shares 10-K · filed 2019-02-26 |
| 2016-09-30 | 16.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 30.93K shares derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | 1.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | 23.67K shares derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | 1.24K shares 10-Q · filed 2017-05-04 | 22.47K shares derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | 11.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | 23.82K shares 10-K · filed 2018-02-27 |
| 2015-09-30 | 9.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | |
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-05-06 | |
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | 0.00 shares 10-K · filed 2017-03-09 |
| 2013-12-31 | 0.00 shares 10-K · filed 2016-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |